Screener
Wave Life Sciences WVE Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Wave Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Wave Life Sciences’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-324949
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Deferred revenue, net of current portion | 13,904 | 7,798 |
| Operating lease liability, net of current portion | 40,082 | 9,405 |
| Total long-term liabilities | 53,986 | 17,203 |
| Total liabilities | $104,801 | $112,268 |
| Series A preferred shares, no par value; nil and 3,901,348 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | — | $7,874 |
| Shareholders’ equity: | ||
| Ordinary shares, no par value; 193,277,622 and 187,660,263 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | $1,627,209 | $1,616,478 |
| Additional paid-in capital | 248,161 | 228,365 |
Item 1. Financial Statements
FAQ
- What is Wave Life Sciences's total liabilities?
- Wave Life Sciences (WVE) reported total liabilities of $104.8M in Q2 2026.
- How has Wave Life Sciences's total liabilities changed year-over-year?
- Wave Life Sciences's total liabilities decreased by 0.4% year-over-year, from $105.22M to $104.8M.
- What is the long-term trend for Wave Life Sciences's total liabilities?
- Over 5 years (2020 to 2025), Wave Life Sciences's total liabilities has grown at a -9.9% compound annual growth rate (CAGR), from $188.59M to $112.27M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Wave Life Sciences's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude